Patent 10442854 was granted and assigned to MedImmune on October, 2019 by the United States Patent and Trademark Office.
Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.